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Alzheimer’s Disease (AD) is described as a gradual decrease in cognition and memory frequently causing 
dementia in most cases. Human microbiome (HM) contribute to the regulation of multiple neuro-chemical and 
neuro-metabolic pathways. The pathological features of AD include amyloid beta peptide (Aβ) deposition, 
neuronal tangle formation and granulovacuolar degeneration. Aβ protein is a normal part of the innate immune 
system, the body's first-line defense against infection. However recent report shows that Aβ expression protects 
against fungal and bacterial infections in mouse, nematode, and cell culture models of AD. Recent reports suggest 
that these proteins are also expressed on bacterial and fungal cell surfaces and might contribute to immune 
response. In addition to commensal microbes, there are other pathogens like Chlamydophila pneumoniae, 
Toxoplasma gondii, Viroids, Hepatitis, Cytomegalovirus have been suspected to be involved in AD. Microbes are 
proposed to play an important role in the pathophysiology of neurodegenerative disease. Microbes are shown to 
produce relevant neurotransmitter, modulate immune response and translocate through blood or lymphatic 
system to brain from the site of infection. Here we elaborated on the emerging ideas showing the contribution of 
the gut microbiome to human neurological diseases with special emphasis on AD. The evidences described here 
may be helpful in designing further studies for taxonomic and functional profiling of microbiota in patients with 
AD which may open doors for advanced therapeutic inventions. 
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Introduction 
Alzheimer’s disease (AD) is characterized by a slowly 
progressive decline of cognition and memory and is the most 
frequent cause of dementia. The major factors for AD are 
unknown, however age is considered as a significant risk 
factor. About 5% of AD cases have a genetic or familial cause 
although the vast majority of all AD cases (~95%) are of 
sporadic origin [1-4]. Disrupted innate immune response, neuro-
immune markers or inflammatory signaling processes are 
crucial in the degenerative process of AD [5-7]. There is 
currently no cure or adequate treatment for AD, and it remains 
unclear how it originates and propagates throughout the brain 
[1]. The pathological features in AD include amyloid beta  
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Figure 1. An overview describing the contents of the review. 
peptide (Aβ) deposition, neuronal tangle formation and 
granulovacuolar degeneration and senile plaques [8]. Mutation 
in epsilon 4 allele of apolipoprotein E (ApoE4)  are 
considered as risk factors [9]. Presenilin 1 and Presenilin 2 
genes are implicated in early onset AD [10]. Polymorphisms in 
various inflammatory genes are also implicated as risk factors 
[11]. The intercellular spreading required for AD ‘staging’ and 
propagation is carried out by small molecular pathogenic 
factors and blood borne neurotoxic elements from the 
environment [12-14]. Aβ protein is a normal part of the innate 
immune system, the body's first-line defense against 
infection. Recent report also shows that Aβ expression 
protects against fungal and bacterial infections in mouse, 
nematode, and cell culture models of AD [14]. Evidences 
suggesting the involvement of innate immune system in the 
onset of AD supports a role for microbes that initiate innate 
immune responses [15, 16]. 
Human Microbiome 
Accumulating evidence has drawn our increased awareness 
towards the relevance of human microbiome and the healthy 
and homeostatic human physiology. Various areas of  the 
human body, including conjunctiva, respiratory tract, oral, and 
otic cavities, and majorly the gastrointestinal tracts (GIT) 
serves as ecosystems for microbial communities comprising 
the human microbiota [1]. The human gut harbors a dynamic 
and complex microbiome consisting of nearly 1014 micro-
organisms spanning over 1000 distinct microbial species 
which outnumber human somatic cells[17-19]. 
GIT is dominated by anaerobic Firmicutes (~51%) and 
Bacteroidetes (~48%). The remaining 1% consist of the 
Proteobacteria, Verrucomicrobia, Fusobacteria, Cyanobact-
eria, Actinobacteria, and Spirochetes other than few species 
of fungi, protozoa and viruses [20]. The microorganisms 
comprising the 1% of the microbiome are also considered 
relevant, as in the case of dysbiosis [17,21,22]. The relationship 
established between the intestinal microbiota and its human 
host provides mutual benefits. During homeostasis, the 
microbiota benefits from the nutrient-rich, warm, environment 
of the gut. In exchange, humans benefit from a highly adaptive 
metabolic engine [18]. The host and microbial communities 
consist mainly of a defined “core microbiome”, despite having 
inter-individual differences at the phylotype level[23]. This 
core microbiome maintains a delicate balance that confers 
health benefits[24]. 
Varying combinations and strains of bacterial species 
amongst human populations might contribute to “human-
biochemical” or “genetic-individuality” and resistance to 
disease[25]. Interestingly, HM participation in human 
physiology may explain the genome-complexity [19, 26, 27] 
(Figure 1). 
HM in neurological disease  
Role of HM in neurological disease is highlighted by studies 
on germ free mice, displaying abnormal behavior and brain 
chemistry. Some of the common gastrointestinal conditions, 
such as irritable bowel syndrome, involving dysbiosis of the 
intestinal microbiota, frequently coexist with psychiatric 
disorders [28].  
Neufeld et al. showed that in the absence of a conventional 
microbiota, female germ free mice show reduced anxiety 
behavior. They also reported simultaneous upregulated  
expression of brain derived neurotrophic factor (BDNF) 
mRNA in the dentate gyrus of the hippocampus [29]. BDNF is 
essential in the maintenance and survival of neurons is known 
to affect neuronal development, differentiation, synapto-
genesis, and the synaptic plasticity that are important for 
neuronal circuit formation and cognition. BDNF was found to  
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Figure 2. Implication of gut microbiota in nervous system and tis communicative factors. 
 
be reduced in the hippocampus and cortex of “germ free” mice, 
and this was associated with increased anxiety behavior and 
progressive cognitive dysfunction [26, 30]. BDNF also has been 
found to be decreased in brain and serum from patients with 
anxiety, behavioral defects, schizophrenia, and AD [31,32]. 
Mice deficient in BDNF showed altered development of GIT 
innervations including the vagus nerve [33,34]. 
In experimental infection models known to lead to 
significant alterations in the microbiota profiles, also show 
reduced BDNF expression in the hippocampus and cortex of 
germ free “gnotobiotic” mice, and this was specifically 
associated with increased anxiety and progressive cognitive 
dysfunction [26, 32]. 
Relevance of HM in pathophysiology of AD  
The host is exposed to the pathogenic microbes and 
symbiotic gut microbiota during their lifetime. Symbiotic gut 
microbiota composition is able to modulate the immune 
system, because metabolic dysfunction in aging facilitates 
obesity. Microbiota and host exposure to pathogens and 
commensals may play crucial role in progression of 
degenerative disorders. The implication of gut microbiome in 
AD is shown in Figure 2. 
Modulation of neurotransmitters by bacteria 
  Members belonging to Gram-positive facultative anaerobic 
or microaerophilic Lactobacillus, and anaerobic 
Bifidobacterium species possess a unique capability of 
metabolizing glutamate to produce gamma aminobutyric acid 
(GABA). GABA is the major inhibitory neurotransmitter in 
the CNS and its signaling dysfunctions are linked to anxiety, 
depression, and cognitive impairment including AD [21,31,35-37]. 
Increased level of GIT γ-aminobutyric acid appears to 
correlate with increased GABA levels in CNS, but the 
systemic pathways that contribute to this linkage between gut 
and brain require additional study [38,39]. Glutamate is the most 
abundant excitatory neurotransmitter in the human CNS and 
is recognized by the N-methyl-D-aspartate (NMDA) receptor 
that regulates synaptic plasticity and cognition. These data 
suggest the possibility of an interaction between 
neurotransmitters and HM.  
Neurotoxin generated by resident microbes or 
environmental pathogens  
 Emerging studies indicate that the HM has highly 
interactive and symbiotic host microbiome signaling systems 
which allow HM to contribute to the regulation of multiple 
neuro-chemical and neuro-metabolic pathways [19].  
Neurotoxins, BMAA is a neurotoxic amino acid normally 
incorporated into the polypeptide chains that constitute brain 
proteins. Elevated levels of BMAA have been reported in the 
brains of patients with amyotrophic lateral sclerosis [40], the 
Parkinson dementia complex of Guam, and AD [41].  
Neurotoxins like saxitoxin and anatoxin, generated by 
Cynobacteria, may further contribute to neurological disease, 
especially when the intestinal epithelial barrier of the GIT 
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becomes significantly more permeable due to aging process 
[41,42]. Ability of bacteria to produce and recognize 
neurochemicals that are exactly analogous in structure to those 
produced by the host nervous system allow them to affect the 
neuro-signaling.  
Bacterial Amyloids 
Amyloid is considered as a major secretory product of 
microbes contributing to the pathophysiology of the human 
central nervous system (CNS). However, recent research has 
shown that these proteins are also expressed on bacterial and 
fungal cell surfaces and might contribute to immune response.  
Aβ42 peptides have the property to initiate a pattern of 
expression of inflammatory genes similar to classical immune 
and inflammatory response induced by infectious agents such 
as bacterial lipopolysaccharide (LPS) [43,44]. The diseases 
having accumulated amyloid as pathological feature, also 
involve a marked inflammatory response at sites of amyloid 
deposition, mediated by microglial cells. Microglial cells 
recognize abnormal forms of amyloid and initiate a phagocytic 
or “clearance” response through Toll like receptor 2 (TLR2) 
[45-47].  
The factors released by gut [45, 48] may potentially modulate 
or alter amyloidosis, neurochemistry, and neurotransmission 
in CNS. The contribution of the gut microorganism and 
bacterial amyloid to protein misfolding and amyloidogenic 
diseases such as AD has been hypothesized and bacterial 
components such as endotoxins are often detected within the 
senile plaque lesions that characterize the AD brain. 
Interestingly, the extracellular 17.7kDa amyloid precursor 
contains a pathogen associated molecular pattern (PAMP) that, 
like the Aβ42 peptide (one of the dominant Aβ peptide 
monomer), is recognized by the human immune system 
TLR2[45,48,49].  
Altered autoimmune response 
  The HM regulates autoimmune responses that can impact 
homeostatic metabolic and neural signaling functions within 
the CNS while constraining the host immunity to foreign 
microbes, including viral infection and xenobiotics [21,50]. 
Neurological disorders have been significantly associated with 
altered autoimmune responses. An increased incidence of auto 
immunity, exposure to pathogens both prenatal and postnatal, 
are common in disorders as diverse as anxiety, autism, 
depression, obsessive compulsive disorder, schizophrenia, PD, 
and AD. This suggests that differences in exposure and genetic 
vulnerability toward HM mediated auto immunity may be 
significant determinants in the course of age related 
neurological disease [21,50-54]. 
MicroRNA (miRNAs) modulation is also considered as a 
mechanism through which gut microbiota show its impact on 
the regulation of host physiology. CSF and extracellular fluid 
of AD patients contains miRNAs as the most abundant nucleic 
acids. The significant increase of miRNA-9, miRNA-125b, 
miRNA-146a, and miRNA-155 have been detected in AD 
CSF compared to age matched controls. Primary human 
neuronal-glial (HNG) cell co-cultures stressed with AD 
derived ECF also displayed an up-regulation of these 
miRNAs[55]. 
Interestingly, both peripherally applied Aβ42 peptides and 
NF-кB regulated pro-inflammatory miRNAs are able to 
induce AD-type changes within brain cells in culture, 
including the dysregulation of innate immune and pro 
inflammatory signaling [56-58]. Studies have also reported the 
involvement of miRNAs in response to bacterial pathogens 
and viral infection, namely in mammalian cells [59]. These 
micro RNAs, including miR-146, miR-155, miR-125, are 
commonly modulated by bacterial infection and contribute to 
immune responses protecting the organism against 
overwhelmed inflammation. This suggests a mechanism 
through which commensal bacteria could impact the 
regulation of the barrier function and intestinal homeostasis. 
Potential neurotropic microorganism in AD 
The potential pathogenic microbes contributing to aging 
and subsequently to AD have been recognized [8,60,22,61-63]. 
Some bacteria are neurotropic by nature and are able to 
influence the nerves tissue by the production of bacterial 
amyloid, lipoproteins and other microbial triggers that can 
activate the microglial TLR2s, subsequently inducing 
cytokine production, inflammation, phagocytosis and innate 
immune defense responses that impact CNS homoeostasis and 
drive neuropathology. It has been observed that the 
TLR2/TLR1 complex can recognize biofilm associated 
amyloids produced by Firmicutes, Bacteroidetes, and 
Proteobacteria [48].  
THE GUT-BRAIN AXIS 
The enteric microbiota interacts with the host to form 
essential relationships that govern homeostasis in a healthy 
individual whereas dysbiosis make important contribution in 
disease pathology [24]. 
This has been established by identifying complex series of 
highly interactive and symbiotic host microbiome signaling 
systems that mechanistically interconnect the GIT, skin, liver, 
and other organs with CNS [18,64]. The bidirectional signaling 
between GIT and brain is vital for maintaining homeostasis 
and is regulated at the neural (both central and enteric nervous 
systems), immunological and hormonal levels. Perturbation of 
these systems results in alterations in the stress-response and 
overall behavior[65].  
Neuronal signaling pathways has structural, metabolic, 
protective functions thus contributing to a number of extra-
intestinal immune-mediated diseases. However they 
remain incompletely understood [18,64]. Neural connections 
involve the central and autonomic nervous systems. The 
brain can upset the gut and vice versa. The central nervous 
system (CNS) communicates with the intestine through 
gut-brain axis, comprising of the hypothalamic-pituitary- 
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Figure 3. Communication between gut, gut microbiota and brain. Possible outcomes of their effect on each other 
influencing overall homeostasis. 
  
 
adrenal axis and, in a gut context, the enteric nervous system 
(ENS). The autonomic nervous system (ANS) consists of 
three components: the sympathetic (noradrenergic) and 
parasympathetic (cholinergic) systems, which originate in the 
CNS (with cell bodies in the brainstem and spinal cord), and 
the enteric system [66] (Figure 3).   
The humoral components of the gut-brain axis consist of the 
hypothalamic-pituitary-adrenal axis, the entero-endocrine 
system and the mucosal immune system. The hypothalamic-
pituitary-adrenal axis is responsible for stress responses, 
resulting in the release of corticosterone, adrenaline and 
noradrenaline. The specialized endocrine cells located in the 
epithelial lining of the gut produce hormones such as 
cholecystokinin and ghrelin, involved in regulating appetite 
and 5-hydroxytryptamine having multiple effects on gut and 
brain functions [67]. 
Studies comparing germ-free and conventional rats showed 
that the microbiota influences the number of gut endocrine 
cells and the release of biologically active peptides [68] 
providing a further mechanism by which the microbiota might 
influence behavior. The intestinal microbiota imprints and 
instructs the mucosal immune system throughout the life of 
the host [69]. The intestinal microbiota is able to influence 
immune activation at sites beyond the GIT and may affect host 
susceptibility to immune-mediated conditions [70]. The 
integrity of the adaptive immune system, and of T lymphocyte 
responses in particular, are crucial for normal learning and 
memory in the mouse[71]. A range of psychiatric disorders, 
including depression implicates the role of pro-inflammatory 
cytokines, including interleukin-4 (IL-4) and interferon-γ [35]. 
Studies have shown that manipulation of the gut microbial 
composition influences systemic cytokine levels in animals 
[72,73] and humans [74]. Administration of B. longum subsp. 
infantis str. 35624 improves depression-like behavior and 
induces increased secretion of IL-6 by peripheral blood cells 
in mice that are subjected to maternal separation [73]. Thus, it 
is possible, that alterations in the intestinal microbiota may 
influence behavior indirectly by affecting cytokine levels in 
the circulation and the brain.   
Perturbed microbiota induced changes in brain chemistry 
and behavior, independent of vagus nerve demonstrates the 
role of microbe originated metabolite[75,76]. A recent study in 
mice showed that the microbiota exerts potential effect on the 
metabolomic profile of the host. The microbiota serves as a 
major source of both circulating organic acids and tryptophan 
metabolites[75,77]. GABA, which has been implicated in 
anxiety, has shown to be produced by commensal lactobacilli 
and bifidobacteria in human indicating that gut bacteria might 
influence behavior via the production of neurotransmitters [39]. 
Some gut bacteria are also able to produce other 
neurochemicals including noradrenaline, 5-hydroxytrypta-
mine receptors (5-HT), dopamine and acetylcholine. The use 
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of these bacteria has been suggested for treatment of 
neuropsychiatric diseases [78]. Moreover, germ-free mice, 
when colonized with bacteria show a >2-fold increase in 5-HT 
and its metabolites owing to bacterial metabolism of 
tryptophan which in turn influence the brain and behavior [77]. 
Alterations in the microbial composition of the gut might 
result in changes in serum kynurenic acid (tryptophan 
metabolite) levels which acts as an antagonist at excitatory 
amino acid receptors, could thus modify central nervous 
system (CNS) excitation and behavior which has been 
implicated in major psychiatric illnesses, including 
schizophrenia [79]. 
Behavior in animals has been reported to be influenced by 
bacterial fermentation products, including lactic acid and 
propionic acid. In a study diet rich in fermentable 
carbohydrates fed to rat, revealed a strong correlation between 
d-lactic acid levels in the caecum and displaying anxiety-like 
behavior and impaired memory [80]. High fecal concentrations 
of propionic acid show correlation with anxiety in patients 
with IBS[81]. Interestingly carbohydrate malabsorption, has 
been associated with depression in females, which may result 
from increased substrate availability for bacterial fermentation 
[82]. Influence of the microbiota on the brain is, further 
evidenced by the observation that behavioral traits of donor 
mice can be adoptively transferred into adult germ-free mice 
of a different strain via the intestinal microbiota. Combining 
these observations, the metabolic products of the intestinal 
microbiota influence brain function and behavior in the host. 
Conclusions 
  This review has presented a detail overview of our current 
understanding on the potential relevance of HM in 
pathophysiology of AD. To have an insights into the gut-brain 
crosstalk during infection, correlation of metabolic and 
neurological phenotypes with the HM profiles have been 
discussed. Further exploring the complex host microbiome 
relationships in healthy human brain vs. aging and during 
neuropsychiatric disease is necessary. Advanced technology 
such as high throughput sequencing and metagenomic 
technologies may further strengthen the suggested association 
with complex microbial ecosystems and may give rise to 
strategies to manipulate HM.  
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